A renewable and genetically tractable human stem cell-derived multicellular platform for the study of fibrotic liver diseases
A renewable and genetically tractable human stem cell-derived multicellular platform for the study of fibrotic liver diseases
批准号:
10576892
负责人:
Charles M Rice
金额:
$49.43万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
未结题
起止时间:
2021-03-01 至 2025-02-28
关键词:
AcidsAddressAffectAnimal ModelAntiviral AgentsCell LineCellsCessation of lifeChronicChronic viral hepatitisCirrhosisClinicClinicalCoculture TechniquesConsensusCytokine GeneDeveloped CountriesDevelopmentDiagnosticDiseaseDisease ProgressionDissectionDrug TargetingElementsEpigenetic ProcessExhibitsExtracellular MatrixFibrosisFunctional disorderGenesGeneticGenetic TranscriptionGenetic studyGlucoseGoalsHealthHepatic Stellate CellHepatitis BHepatitis CHepatitis C virusHepatocyteHumanIn VitroIndividualInflammatoryInflammatory ResponseInsulinInsulin ResistanceInterventionKineticsKnowledgeLifeLife StyleLinkLipidsLiverLiver FibrosisLiver diseasesMacrophageMeasurableMediatingMetabolic DiseasesModelingMolecularMyofibroblastNonesterified Fatty AcidsOutcomePathogenesisPathway interactionsPatientsPhenotypePhysiologyPopulationPredispositionProcessPublic HealthRegimenResearchRisk FactorsRoleSignal TransductionStimulusStressSupporting CellSystemTestingTransforming Growth Factor betaVariantViralViral hepatitisVirus DiseasesVirus ReplicationWorkantifibrotic treatmentbaseburden of illnesscell immortalizationcell typechronic liver diseaseclinical phenotypeclinically relevantconnective tissue growth factorcytokinedesigneffective therapyexposed human populationfibrogenesisgenetic risk factorgenetic varianthuman pluripotent stem cellhuman stem cellsimprovedinnovationinsightnon-alcoholic fatty liver diseasenovelnovel diagnosticsnovel therapeuticspatient subsetspreventprofibrotic cytokinestellate celltherapeutic developmenttranscriptometransdifferentiationvirtual
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary
Fibrotic liver disease is a growing public health concern significantly impacting the global population. Fibrotic
liver disease is often the result of sustained insults; chronic viral hepatitis B and C as well as NAFLD are the
most prevalent causes. While antiviral regimens for hepatitis B and C have decreased the viral cirrhosis burden,
other causes like NAFLD are increasingly prevalent, now affecting 14-27% of individuals in developed countries.
Despite this high disease burden, there are currently no approved therapies. Rather, the lack of consensus
on optimal drug targets or strategies reflects a gap in our mechanistic understanding of disease drivers. Similarly,
the utility and clinical relevance of animal models is equally controversial. A multitude of models are currently
used, but each recapitulates only isolated aspects of human pathophysiology. There is an unmet need for
human-relevant systems that recapitulate key elements of fibrotic liver disease to enable mechanistic dissection.
The measurable improvement in liver fibrosis in some but not all patients following successful antiviral
treatment reinforces the need for better understanding of fibrogenesis at a molecular level to aid development of
new treatments to prevent fibrosis or encourage regression. For NAFLD, despite identification of increasing
numbers of susceptibility-associated genetic variants and lifestyle-dependent risk factors, the mechanisms by
which they individually or synergistically contribute to disease progression remain largely unclear.
The primary research goal of this proposal is to exploit a unique renewable and genetically manipulatable
human pluripotent stem cell (hPSC)-derived multicellular culture system to address the aforementioned gaps. In
this multicellular system, we coculture hPSC-derived hepatocytes, hepatic stellate cells (HSCs), and
macrophages in a manner that recapitulates the complexity of liver physiology in both health and disease.
Modeling hepatitis virus infection and NAFLD in the multicellular cultures, we found that both HCV infection and
a lipotoxic milieu induced inflammatory signals and stellate cell activation. A lipotoxic milieu also triggered other
features of NAFLD clinical phenotypes. Eliminating HCV reversed fibrosis-like phenotypes and treating with
obeticholic acid showed improvement in NAFLD-like features, as observed in the clinic.
Across three aims, using cell and molecular approaches, we capitalize on the unique features of this novel
platform to address questions that cannot be adequately answered with any existing ex vivo human-relevant
system, including the roles of cytokines in HSC activation (Aim 1), the mechanisms of reversion after activation
(Aim 2) and the role of genetics and lifestyle-associated risk factors in NAFLD (Aim 3). Understanding the
molecular mechanisms of stellate cell activation and fibrosis development are critical for developing diagnostics
and designing new treatments to block fibrosis or promote regression. In addition, elucidating the mechanisms
of how genetic variants and risk factors contribute to liver disease progression may offer the opportunity to craft
targeted antifibrotic interventions optimized for particular patient subgroups.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Employing viruses to unravel the functional significance of the m5C epitranscriptome
-
批准号:10638533
-
项目类别:
-
资助金额:$66.0万
-
财政年份:2023
-
负责人:Charles M Rice
-
依托单位:
Elucidating the mechanism by which ADAR1 prevents autoimmunity against self RNA
-
批准号:10667182
-
项目类别:
-
资助金额:$25.43万
-
财政年份:2023
-
负责人:Charles M Rice
-
依托单位:
Tracking SARS-CoV-2 one molecule at a time: Spatiotemporal investigation of coronavirus replication dynamics and host response in single cells in vitro and in vivo
-
批准号:10446423
-
项目类别:
-
资助金额:$63.76万
-
财政年份:2022
-
负责人:Charles M Rice
-
依托单位:
A clear view of encephalitis: a single cell approach to determine the basis of flaviviral pathogenesis in the central nervous system
-
批准号:10553697
-
项目类别:
-
资助金额:$62.82万
-
财政年份:2022
-
负责人:Charles M Rice
-
依托单位:
Tracking SARS-CoV-2 one molecule at a time: Spatiotemporal investigation of coronavirus replication dynamics and host response in single cells in vitro and in vivo
-
批准号:10570297
-
项目类别:
-
资助金额:$61.93万
-
财政年份:2022
-
负责人:Charles M Rice
-
依托单位:
Scientific Core: BSL3 Virology and Animal Models
-
批准号:10327991
-
项目类别:
-
资助金额:$145.45万
-
财政年份:2022
-
负责人:Charles M Rice
-
依托单位:
Scientific Core: BSL3 Virology and Animal Models
-
批准号:10841239
-
项目类别:
-
资助金额:$98.31万
-
财政年份:2022
-
负责人:Charles M Rice
-
依托单位:
A clear view of encephalitis: a single cell approach to determine the basis of flaviviral pathogenesis in the central nervous system
-
批准号:10446620
-
项目类别:
-
资助金额:$68.19万
-
财政年份:2022
-
负责人:Charles M Rice
-
依托单位:
Virology Core
-
批准号:10513915
-
项目类别:
-
资助金额:$528.97万
-
财政年份:2022
-
负责人:Charles M Rice
-
依托单位:
TMEM41B: a pan-flavivirus and pan-coronavirus host factor with antiviral potential
-
批准号:10587597
-
项目类别:
-
资助金额:$46.09万
-
财政年份:2022
-
负责人:Charles M Rice
-
依托单位:
TMEM41B: a pan-flavivirus and pan-coronavirus host factor with antiviral potential
-
批准号:10707260
-
项目类别:
-
资助金额:$61.01万
-
财政年份:2022
-
负责人:Charles M Rice
-
依托单位:
A renewable and genetically tractable human stem cell-derived multicellular platform for the study of fibrotic liver diseases
-
批准号:10360541
-
项目类别:
-
资助金额:$49.43万
-
财政年份:2021
-
负责人:Charles M Rice
-
依托单位:
A renewable and genetically tractable human stem cell-derived multicellular platform for the study of fibrotic liver diseases
-
批准号:10211567
-
项目类别:
-
资助金额:$50.99万
-
财政年份:2021
-
负责人:Charles M Rice
-
依托单位:
Defining therapeutic drug targets for SARS-CoV-2-specific and pan-coronavirus inhibition
-
批准号:10238377
-
项目类别:
-
资助金额:$48.35万
-
财政年份:2021
-
负责人:Charles M Rice
-
依托单位:
Launching HBV with RNA to assess antiviral resistance and explore fundamental aspects of virus-host biology
-
批准号:10555333
-
项目类别:
-
资助金额:$61.11万
-
财政年份:2020
-
负责人:Charles M Rice
-
依托单位:
Identification of host factors required by the tick-borne Powassan virus
-
批准号:10154884
-
项目类别:
-
资助金额:$25.43万
-
财政年份:2020
-
负责人:Charles M Rice
-
依托单位:
Identification of host factors required by the tick-borne Powassan virus
-
批准号:10307148
-
项目类别:
-
资助金额:$21.19万
-
财政年份:2020
-
负责人:Charles M Rice
-
依托单位:
In search of an HBV cure: novel model systems and targets
-
批准号:10400212
-
项目类别:
-
资助金额:$59.43万
-
财政年份:2019
-
负责人:Charles M Rice
-
依托单位:
HEP DART 2019: Frontiers in Drug Development for Hepatology
-
批准号:9914390
-
项目类别:
-
资助金额:$0.85万
-
财政年份:2019
-
负责人:Charles M Rice
-
依托单位:
In search of an HBV cure: novel model systems and targets
-
批准号:10633080
-
项目类别:
-
资助金额:$59.43万
-
财政年份:2019
-
负责人:Charles M Rice
-
依托单位:
海外基金